April 29 (Reuters) - The U.S. Food and Drug Administration granted traditional approval for Pfizer's drug for cervical cancer patients with disease progression on or after chemotherapy, the agency said on Monday. (Reporting by Pratik Jain in Bengaluru; Editing by Anil D'Silva)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
28.6 USD | -1.09% | +2.12% | -0.64% |
07:55pm | Sector Update: Health Care Stocks Softer Friday Afternoon | MT |
07:42pm | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.64% | 164B | |
+32.35% | 694B | |
+29.39% | 593B | |
-1.55% | 371B | |
+20.12% | 331B | |
+7.21% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.60% | 169B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- US FDA grants full approval for Pfizer's cervical cancer drug